UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 278

Sortiert nach

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

The journal of clinical endocrinology and metabolism, 2018-08, Vol.103 (8), p.2949-2957

2018

Volltextzugriff (PDF)

Effects of Abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial

Bone (New York, N.Y.), 2017-04, Vol.97, p.314-319

2017

Volltextzugriff (PDF)

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study

JBMR plus, 2020-04, Vol.4 (4), p.e10346-n/a

2020

Volltextzugriff (PDF)

Pathophysiology of bone loss in patients receiving anticonvulsant therapy

Epilepsy & behavior, 2004-02, Vol.5, p.3-15

Fitzpatrick, Lorraine A.

2004

Volltextzugriff (PDF)

Calcification in Atherosclerosis: Bone Biology and Chronic Inflammation at the Arterial Crossroads

Proceedings of the National Academy of Sciences - PNAS, 2003-09, Vol.100 (20), p.11201-11206

2003

Volltextzugriff (PDF)

Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification

Endocrine reviews, 2004-08, Vol.25 (4), p.629-672

2004

Volltextzugriff (PDF)

Parathyroid hormone and the cardiovascular system

Current osteoporosis reports, 2008-06, Vol.6 (2), p.77-83

2008

Volltextzugriff (PDF)

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-08, Vol.316 (7), p.722

2016

Volltextzugriff (PDF)

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension

Yonsei Medical Journal, 2016, 57(4), , pp.905-914

2016

Volltextzugriff (PDF)

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Bone Reports, 2019-12, Vol.11, p.100230-100230, Article 100230

2019

Volltextzugriff (PDF)

Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis

Yonsei Medical Journal, 2016, 57(4), , pp.923-927

2016

Volltextzugriff (PDF)

Effects of Abaloparatide‐SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors

Journal of bone and mineral research, 2017-01, Vol.32 (1), p.17-23

2017

Volltextzugriff (PDF)

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial

Mayo Clinic proceedings, 2017-02, Vol.92 (2), p.200-210

2017

Volltextzugriff (PDF)

Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture

Seminars in arthritis and rheumatism, 2019-10, Vol.49 (2), p.184-196

2019

Volltextzugriff (PDF)

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

Current medical research and opinion, 2019-12, Vol.35 (12), p.2097-2102

2019

Volltextzugriff (PDF)

Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective

Seminars in arthritis and rheumatism, 2020-06, Vol.50 (3), p.394-400

2020

Volltextzugriff (PDF)

Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis

Current medical research and opinion, 2020-11, Vol.36 (11), p.1861-1872

2020

Volltextzugriff (PDF)

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis

Menopause (New York, N.Y.), 2018-07, Vol.25 (7), p.767

2018

Volltextzugriff (PDF)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

Menopause (New York, N.Y.), 2020-10, Vol.27 (10), p.1137

2020

Volltextzugriff (PDF)

Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

Journal of bone and mineral research, 2007-12, Vol.22 (12), p.1832-1841

2007

Volltextzugriff (PDF)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

Calcified tissue international, 2018-06, Vol.102 (6), p.627-633

2018

Volltextzugriff (PDF)

Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus

The journal of clinical endocrinology and metabolism, 2013-04, Vol.98 (4), p.1519-1528

2013

Volltextzugriff (PDF)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis

Indian journal of endocrinology and metabolism, 2015-01, Vol.19 (1), p.148-154

2015

Volltextzugriff (PDF)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide

Calcified tissue international, 2018-11, Vol.103 (5), p.540-545

2018

Volltextzugriff (PDF)

Rationale for the role of osteoclast‐like cells in arterial calcification

The FASEB journal, 2002-04, Vol.16 (6), p.577-582

2002

Volltextzugriff (PDF)

1 – 25 von 278

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(257)
Mit Volltextzugriff
(240)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(167)
Life Sciences & Biomedicine
(159)
Humans
(121)
Biological And Medical Sciences
(91)
Female
(86)
Medical Sciences
(65)
Endocrinology & Metabolism
(64)
Animals
(54)
Male
(49)
Middle Aged
(46)
Aged
(43)
Fundamental And Applied Biological Sciences. Psychology
(36)
Osteoporosis
(36)
General & Internal Medicine
(32)
Medicine, General & Internal
(30)
Adult
(29)
Aged, 80 And Over
(25)
Bone Density - Drug Effects
(20)
Bone Density
(18)
Vertebrates: Endocrinology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Effects of Abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study

Pathophysiology of bone loss in patients receiving anticonvulsant therapy

Calcification in Atherosclerosis: Bone Biology and Chronic Inflammation at the Arterial Crossroads

Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification

Parathyroid hormone and the cardiovascular system

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis

Effects of Abaloparatide‐SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial

Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective

Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide

Rationale for the role of osteoclast‐like cells in arterial calcification

Suchergebnisse filtern